Note 8 - Subsequent Events |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Notes to Financial Statements | |
| Subsequent Events [Text Block] |
Note 8 - Subsequent Events
The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q and determined that there have been no recognized subsequent events that have occurred that would require adjustments to the Company’s disclosures in the condensed consolidated financial statements. The following are nonrecognized subsequent events through the filing of this Quarterly Report on Form 10-Q.
Share Issuances
On April 1, 2026, Genprex issued 5,000 shares of its common stock to the Chairman of its Scientific Advisory Board in consideration for services.
At-The-Market Offering
From April 1, 2026 through the date of filing of this Quarterly Report on Form 10-Q, Genprex has sold 1,536,546 shares of its common stock for aggregate net proceeds to the Company totaling approximately $1.90 million under the 2023 ATM Facility.
|